One Target, Five Antibodies: Why Anti-CD20 Mechanism Now Decides Outcomes in Lymphoma, MS, and Lupus Nephritis

https://www.medscape.com/c99/p10/one-target-five-antibodies-why-anti-cd20-mechanism-now-2026a10010oz?src= In October 2025, obinutuzumab became the first anti-CD20 monoclonal antibody to win an FDA indication for active lupus nephritis. Gazyva PI Two earlier placebo-controlled trials of the Type I antibodies rituximab and ocrelizumab in proliferative lupus nephritis had failed to show a statistically significant benefit on renal response. Furie ARD 2022Readers should be aware of an important safety context behind the ocrelizumab trial (BELONG): it was not simply neutral on efficacy, it was stopped early by the sponsor specifically because of a safety signal, an imbalance in serious and opportunistic infections in ocrelizumab-treated patients compared with placebo, most notably a 3.2% vs 0.8% rate of serious opportunistic infections in the 400 mg ocrelizumab arm. Mysler Arthritis Rheum 2013